Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report Findings:
- Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
- Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
- Peptide Therapeutics in Clinical Trials: > 800 Drugs
- Peptide Therapeutics Commercially Available In Market: > 200 Drugs
- Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides
Download Report Sample:
https://www.kuickresearch.com/ccformF.php?t=1650627251
Since last decade, peptides have emerged as one of the most promising therapeutic agents in the in treatment of malignancy, diabetes, cardiovascular disease and the application is growing rapidly. Therapeutic peptides confer several advantages over the conventional methods: they are small in size which makes them suitable to penetrate in all cell membranes; they can be easily synthesized and modified as per the target cell. They also have high specificity and activity and minimal drug interaction. They do not accumulate in body parts like kidney or liver, which minimizes the toxicity of these peptides. The high research and development in this sector has led to development of several peptide therapeutics, among which 200 has gained approval in the market.
Peptide drug conjugates represents one the most promising approach in peptide therapeutics owing to its high specificity and targeted nature. TH1902 developed by Theratechnologies is one of the promising peptide drug conjugate in clinical development which is based on Theratechnologies’ SORT1+ Technology™ in oncology. In May 2022, the company has initiated the enrollment for phase-I clinical trial evaluating the drug for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy. Preclinical studies have demonstrated that the drug has the potential to accumulate 7.5 to 10 times more docetaxel in cancer cells in comparison to the administration of docetaxel alone.
Currently, most of the peptides administered to the patients are in injectable form. Developments are being going on for alternative methods of administration such as oral, transdermal routes. One such study has been done in the transbuccal delivery through combination of gold nanoparticles (Midatech) and the PharmFilm™ (Monosol Rx) technology. Another example is the TopAct™ technology platform from ActoGeniX, which might enable oral delivery of peptides directly expressed in the gastrointestinal tract. The coming years will see new routes of peptide therapeutics which will enhance its adoption among large population.
The global peptide therapeutics market is highly competitive with several key players including Amgen, Eli Lilly, Galena Biopharmaceuticals, Merck, Roche, PpetiDream, and others. These companies have also adopted strategic alliances to maintain position in their global market. Recently in 2022, Fusion Pharma and 48 Hour Discovery has announced collaboration to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. In addition, Fusion Pharma also announced collaboration with Merck to access the safety of FPI-1434 in combination with Keytruda for the treatment of solid tumors expressing IGF-1R.
As per our report findings, the global peptide therapeutics market is expected to surpass US$ 75 Billion by 2028. The market is registering high growth which is maily attributable to several factors including surge in prevalence of chronic diseases, rising expenditure in healthcare, scientific and technological advancement in peptide manufacturing, and robust sales of approved drugs. In addition, huge investments by the pharmaceutical giants in this sector will also have positive impact on the growth of market. Further, availability of cost-effective generic drugs also enhances the accessibility of these drugs among large population. However, stringent regulatory guidelines and failure of drugs in late stage clinical trials hamper the growth of market.
Our report provides in-depth analysis on the currently approved peptide therapeutics in the market along with their pricing, dosage, and sales analysis. The report also identifies key drivers and challenges which affect the growth of market during the forecast period. This report forecasts revenue growth at global and regional levels and provides an analysis of the latest trends and opportunities. The report also gives information on the ongoing clinical trials in market with major drugs in research and development across various stages. Competitive landscape of major companies investing in the market is also mentioned.</P
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366